AxoGen announces independent publication on allograft, autograft, conduits

Axogen announced the independent publication of a comprehensive, retrospective clinical review comparing the meaningful recovery rates between allograft, autograft, and conduits using a meta-analysis methodology. The comparative peer-reviewed analysis was published online ahead of print by Plastic and Reconstructive Surgery. The publication, "A systematic review and meta-analysis of nerve gap repair: Comparative effectiveness of allografts, autografts, and conduits," analyzed 35 peer-reviewed studies with a total of 1,559 nerve repairs including 711 nerve allograft, 670 autograft, and 178 conduit repairs. The analysis concluded that meaningful recovery rates for allograft and autograft repairs were comparable across all gap lengths up to 70 millimeters. There were no statistical differences between allograft and autograft outcomes for either short or long gap lengths for both sensory and motor repairs. Allograft and autograft repairs delivered significantly better rates of meaningful sensory recovery in short gaps as compared to conduit repairs; 87.1% and 81.6% vs. 62.2%, respectively. The cost analysis found that allograft does not represent an increased economic burden compared to autograft. "This paper provides the strongest clinical evidence to-date of the performance of Avance Nerve Graft, the nerve allograft included in this study, across all gap lengths and nerve types. This comprehensive analysis of peer-reviewed studies illustrates that compared to autograft, Avance is just as effective, with similar procedure costs, while eliminating the potential for complications or reduced quality of life resulting from autograft nerve harvesting," commented Karen Zaderej, chairman, CEO, and president of Axogen, Inc. "With more than 50,000 implants since launch, Avance is a proven solution for providing patients the opportunity to achieve meaningful functional recovery without the need for autograft harvest."